

Supplementary Table 4. Kaplan Meier Univariate Analysis of Overall Survival in the Global Study Population (N=213)

Parameters	N	Overall Survival (Kaplan Meier)		
		Median (95%CI)	Hazard Ratio (95%CI)	Log-rank p-value
General variables				
Age at diagnosis; years				
>=45 [ref.]	177	8.2 (6.2 - 10.4)		
<45	36	35.6 (17.8 - 35.6)	0.176 (0.062 - 0.389)	<0.0001 *
>=55 [ref.]	149	6.5 (5.7 - 8.7)		
<55	64	17.8 (15.3 - 35.6)	0.270 (0.150 - 0.454)	<0.0001 *
Gender				
Female [ref.]	126	12.5 (8.7 - 16.2)		
Male	87	7.3 (5.4 - 17.8)	1.399 (0.939 - 2.072)	0.0942
Variables of initial diagnosis and first treatment				
Histology				
Papillary [ref.]	125	14.9 (8.7 - 16.8)		
Follicular	39	6.4 (5.1 - 11.1)	1.520 (0.907 - 2.460)	0.4213
Hürthel	21	12.5 (5.8 - 17.6)	1.132 (0.561 - 2.078)	
Others	24	NE (4.3 - NE)	1.203 (0.596 - 2.210)	
Diagnosis type				
Recurrent [ref.]	98	15.3 (10.4 - 17.8)		
Novo	115	6.4 (5.1 - NE)	2.381 (1.559 - 3.698)	<0.0001 *
Surgery				
R2 [ref.]	23	5.1 (2.4 - 5.2)		
R0/R1	172	12.5 (8.7 - 16.2)	0.282 (0.170 - 0.494)	<0.0001 *
Others ⁽¹⁾	13	17.8 (5.1 - 35.6)	0.236 (0.084 - 0.574)	
Surgical extension				
Thyroidectomy total [ref.]	137	11.1 (8.2 - 17.6)		
Thyroidectomy partial + others ⁽²⁾	72	10.4 (6.4 - 16.8)	1.171 (0.772 - 1.751)	0.4471

Parameters	N	Overall Survival (Kaplan Meier)		
		Median (95%CI)	Hazard Ratio (95%CI)	Log-rank p-value
Disease extension				
Locoregional [ref.]	14	8.6 (0.7 - 12.5)		
Metastatic	199	10.4 (7.3 - 16.0)	0.617 (0.319 - 1.383)	0.1869
Ablative RAI +/- local therapies				
Yes [ref.]	190	11.1 (8.6 - 17.6)		
No	23	3.0 (0.5 - 12.5)	2.480 (1.439 - 4.038)	0.0003 *
RAI Refractoriness at initial diagnosis				
No [ref.]	200	11.1 (8.6 - 16.2)		
Yes	13	0.7 (0.3 - 3.1)	6.018 (3.008 - 10.903)	<0.0001 *
RAI Cumulative dose				
>=600 mCi [ref.]	29	11.1 (6.5 - 17.8)		
<600 mCi	160	9.5 (7.2 - 16.2)	1.411 (0.782 - 2.815)	0.0013 *
No RAI treatment ⁽³⁾	23	3.0 (0.5 - 12.5)	3.267 (1.556 - 7.171)	
RAI with stimulating agent at first instance ⁽⁴⁾				
No [ref.]	136	14.9 (8.6 - 17.8)		
Yes	46	10.4 (5.5 - NE)	1.286 (0.767 - 2.081)	0.3195
RAI Response at first instance. ATA criteria ⁽⁵⁾				
Excellent [ref.]	18	NE (8.6 - NE)		
Biochemical Incomplete + Indeterminate	53	11.1 (7.2 - 16.2)	2.821 (1.090 - 9.606)	0.0159 *
Structural Incomplete	117	8.7 (6.2 - NE)	3.885 (1.570 - 12.949)	
RAI-scan positivity after initial RAI ⁽⁶⁾ treatment				
No [ref.]	26	17.8 (9.2 - NE)		
Yes	133	9.5 (7.1 - 16.2)	1.897 (0.989 - 4.038)	0.0678

(1): Resection of other lesions such as adenopathy or metastasis. (2): Pathological lymph node dissections or metastasectomies; RAI, Radioactive Iodine (I-131). (3): Patients

Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.

Juan Antonio Vallejo Casas^{1*}; Marcel Sambo^{2*}; Carlos López López³ and Manuel Durán-Poveda⁴ on behalf of the ERUDIT Study group

not receiving RAI because of it not being clinically indicated or having tumours with negative RAI scans. (4): Following standard practice in Spain and Portugal, patients not receiving hrTSH prior to RAI, were deprived of LT4. (5): Haugen et al., 2016 (1). (6): Refers to 6-12 months follow-up post-treatment scans in patients that could have received surgery ± RAI as first therapeutic approach (Types 1, 3, and 4). [ref.]: Reference category. CI: Confidence interval. NE: Non-Estimable. R0: Microscopic complete resection. R1: Macroscopic resection with microscopic residual tumour. R2: Gross macroscopic residual tumour. (*): Statistically significant ($p < 0.05$).